

A detailed microscopic image of tissue, likely showing cellular structures and possibly a large, dark, circular lesion or inclusion body, serving as a background for the top half of the slide.

Data Featured at ACG 2026

Johnson & Johnson

American College of
Gastroenterology

Nashville, Tennessee
October 9-14

J&J Sponsored R&D Studies

Abstract numbers	Title	Presentation time (CDT)
<i>Guselkumab studies</i>		
<i>FUZION study</i>		
Poster Presentation		
P5691	Efficacy of guselkumab in perianal fistulizing Crohn's disease: Week 24 results from the Phase 3, randomized, double-blind, placebo-controlled, multicenter FUZION study	Tuesday, October 13 10:30 a.m. – 4:00 p.m.

<i>GALAXI studies</i>		
Poster Presentations		
P3333	Deep remission in guselkumab-treated participants with moderately to severely active Crohn's disease through 3 years: Results from the GALAXI 2 & 3 studies	Monday, October 12 10:30 a.m. – 4:15 p.m.
P5693	Efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Results through Week 144 from the Phase 3 GALAXI 2 & 3 studies	Tuesday, October 13 10:30 a.m. – 4:00 p.m.

<i>GALAXI/GRAVITI studies</i>		
Podium Presentation		
OP38	Changes in intestinal stenosis among patients with moderately to severely active Crohn's disease treated with guselkumab: Results from the Phase 3 GALAXI & GRAVITI studies	Tuesday, October 13 2:25 – 2:35 p.m.
Poster Presentations		
P5695	Endoscopic outcomes of ulcer size and ulcerated surface over one year across bowel segments in participants with Crohn's disease treated with guselkumab: Pooled GALAXI 2 & GALAXI 3, Phase 3 trials analysis	Tuesday, October 13 10:30 a.m. – 4:00 p.m.
P5692	Pharmacokinetics and exposure-response relationships of subcutaneous guselkumab maintenance in participants with moderately to severely active Crohn's disease	Tuesday, October 13 10:30 a.m. – 4:00 p.m.

<i>QUASAR/ASTRO studies</i>		
Poster Presentation		
P3333	Pharmacokinetics and exposure-response relationships of subcutaneous guselkumab maintenance in participants with moderately to severely active ulcerative colitis	Monday, October 12 10:30 a.m. – 4:15 p.m.

<i>ASTRO study</i>		
Poster Presentations		
P1180	Unsupervised machine learning to identify distinct response patterns to guselkumab in participants with ulcerative colitis: Post hoc analysis from the ASTRO study	Sunday, October 11 3:30 – 7:00 p.m.
P1177	The efficacy and safety of guselkumab in patients with moderate to severe ulcerative colitis through 2 years: ASTRO Week 96 results	Sunday, October 11 3:30 – 7:00 p.m.

<i>QUASAR study</i>		
Podium Presentation		
OP43	Histology over time in patients with moderately to severely active ulcerative colitis treated with guselkumab in the QUASAR long-term extension study Awarded ACG Governors Award for Excellence in Clinical Research	Tuesday, October 13 3:15 – 3:25 p.m.
Poster Presentations		
P3358	Time to indicators of disease progression in patients with moderately to severely active ulcerative colitis: Results from the guselkumab Phase 3 QUASAR maintenance study	Monday, October 12 10:30 a.m. – 4:15 p.m.
P3359	Symptomatic and biomarker outcomes through Week 24 among participants not in clinical response at Week 12 treated with guselkumab: Results from the QUASAR study	Monday, October 12 10:30 a.m. – 4:15 p.m.

<i>Icotrokinra studies</i>		
<i>ANTHEM study</i>		
Podium Presentation		
OP41	Long-term efficacy and safety of icotrokinra, a first-in-class targeted oral peptide that precisely blocks the IL-23 receptor, in ulcerative colitis: Results from the ANTHEM-UC LTE	Tuesday, October 13 2:55 – 3:05 p.m.
Poster Presentation		
P1053	Histologic and endoscopic efficacy of icotrokinra, a first-in-class targeted oral peptide that precisely blocks the IL-23 receptor, in ulcerative colitis: Outcomes from the ANTHEM-UC study	Sunday, October 11 3:30 – 7:00 p.m.

<i>JNJ-4804 studies</i>		
<i>DUET-CD study</i>		
Poster Presentation		
P5694	Efficacy and safety of the first co-antibody therapy, JNJ-78934804, in patients with moderately to severely active Crohn's disease refractory to two or more systemic therapy mechanisms	Tuesday, October 13 3:30 – 7:00 p.m.

Market Access and Real-World Evidence

Abstract numbers	Title	Presentation time (CDT)
<i>RWE study</i>		
Poster Presentations		
P5687	Prevalence, unmet needs, treatment patterns and healthcare resource utilization of patients with fistulizing Crohn's disease	Tuesday, October 13 10:30 a.m. – 4:00 p.m.
P5686	Patient characteristics, treatment patterns, and healthcare resource utilization in patients with inflammatory bowel disease who initiated treatment with guselkumab	Tuesday, October 13 10:30 a.m. – 4:00 p.m.

<i>Adelphi study</i>		
Poster Presentation		
P1076	Healthcare professionals' perceptions of intravenous and subcutaneous treatment administration for inflammatory bowel disease; a real-world study in the United States	Sunday, October 11 3:30 – 7:00 p.m.

Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.